Lata Jayaraman

Infrafrontier — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index3.1kcitations73works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(25), Synthesis and biological activity(12), Epigenetics and DNA Methylation(10), Nanoplatforms for cancer theranostics(10), Gut microbiota and health(6)

Publications73 total

Abstract B123: FMC-220, a highly potent and selective covalent activator of p53 Y220C, is broadly active in p53 Y220C containing PDX models across cancer indications
Molecular Cancer Therapeutics·2025
Abstract 3787: Restoring the function of the guardian of the genome: FMC-220 a highly potent and selective covalent activator of p53 Y220C
Cancer Research·2025
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1
Bioorganic & Medicinal Chemistry Letters·2023· 5 citedOpen Access
Supplementary Information Figure S3 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S2 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S5 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information text S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Table S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S5 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S4 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Figures from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Data from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Supplementary Information text S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Figure Legends from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Supplementary Information Figure S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S4 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Information Figure S3 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Data from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Data from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
Supplementary Table S1 from Dissecting Therapeutic Resistance to ERK Inhibition
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Scott Eliasof(14), Christian Peters(13), Erick J. Morris(12), Sharda Jha(12), Clifford R. Restaino(12), Priya Dayananth(12), Alan Hruza(12), Leigh Zawel(12), Stephen E. Fawell(12), Ahmed A. Samatar(12), Stuart Black(10), My Sam Mansueto(9), Gottfried K. Schroeder(9), Jaren Arbanas(9), Daniel R. McMasters(9), Nathaniel L. Elsen(9), Anthony Mannarino(9), Edward G. Garmey(6), Ellen Rohde(6), Henry P. Foote(5)